Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Sherbrooke Park Advisers LLC

Sherbrooke Park Advisers LLC reduced its stake in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 57.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,645 shares of the medical equipment provider's stock after selling 7,580 shares during the period. Sherbrooke Park Advisers LLC's holdings in Hologic were worth $407,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Principal Financial Group Inc. increased its stake in Hologic by 0.6% during the fourth quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider's stock worth $19,547,000 after acquiring an additional 1,606 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in Hologic by 44.7% during the fourth quarter. Nisa Investment Advisors LLC now owns 63,744 shares of the medical equipment provider's stock worth $4,595,000 after acquiring an additional 19,688 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its stake in Hologic by 11.4% during the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 68,427 shares of the medical equipment provider's stock worth $4,933,000 after acquiring an additional 6,986 shares during the last quarter. Groupama Asset Managment increased its stake in Hologic by 63.4% during the fourth quarter. Groupama Asset Managment now owns 54,214 shares of the medical equipment provider's stock worth $3,918,000 after acquiring an additional 21,037 shares during the last quarter. Finally, Avanza Fonder AB acquired a new stake in Hologic during the fourth quarter worth about $1,861,000. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Stock Up 0.1%

HOLX stock traded up $0.04 during midday trading on Tuesday, hitting $56.47. 1,897,863 shares of the company's stock were exchanged, compared to its average volume of 2,128,179. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $84.67. The firm has a 50 day moving average price of $58.59 and a 200-day moving average price of $67.07. The stock has a market capitalization of $12.58 billion, a price-to-earnings ratio of 17.81, a price-to-earnings-growth ratio of 2.14 and a beta of 0.54.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The company's revenue for the quarter was down 1.2% compared to the same quarter last year. During the same period last year, the firm earned $1.03 earnings per share. On average, analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Insider Buying and Selling

In other news, Director Martin D. Madaus purchased 5,445 shares of the firm's stock in a transaction that occurred on Wednesday, May 7th. The stock was acquired at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the purchase, the director now owns 5,445 shares of the company's stock, valued at approximately $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.88% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on HOLX shares. Leerink Partnrs cut shares of Hologic from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 6th. Royal Bank of Canada decreased their price target on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a research report on Friday, May 2nd. Raymond James reaffirmed an "outperform" rating and set a $71.00 price target (down from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Leerink Partners cut shares of Hologic from an "outperform" rating to a "market perform" rating and decreased their price target for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th. Finally, Evercore ISI reduced their target price on shares of Hologic from $65.00 to $62.00 and set an "in-line" rating on the stock in a research report on Friday, May 2nd. Twelve equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Hologic currently has an average rating of "Hold" and an average target price of $77.42.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.